{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:02:44Z","timestamp":1782741764336,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pexidartinib (Turalio) is the only systemic therapy approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant-cell tumor (TGCT) associated with severe morbidity or functional limitations, and not amenable to improvement with surgery. This study assessed patient-reported treatment experiences and symptom improvement among patients receiving pexidartinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional, web-based survey collected data on demographics, disease history, pexidartinib dosing, and symptoms before and after pexidartinib use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 288 patients enrolled in the Turalio REMS program in May 2021, 83 completed the survey: mean age was 44.2 years, 62.7% were female, and most common tumor sites were in knee (61%) and ankle (12%). Mean initial dose was 622 mg\/day: 29 patients reported reduction from initial dose and 8 had dose reduction after titrating up to a higher dose. At the time of survey completion, median time on pexidartinib was 6.0 months; 22 (26.5%) patients discontinued pexidartinib due to physician suggestion, abnormal laboratory results, side effect, or symptom improvement. Compared with before pexidartinib initiation, most patients reported improvement in overall TGCT symptom (78.3%) and physical function (77.2%) during pexidartinib treatment. Significant improvement was reported during pexidartinib treatment in worst stiffness numeric rating scale (NRS) (3.0 vs. 6.2, P\u2005&amp;lt;\u2005.05) and worst pain NRS (2.7 vs. 5.7, P\u2005&amp;lt;\u2005.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Findings from this cross-sectional survey confirmed the benefit of pexidartinib in improving symptoms and functional outcomes among patients with symptomatic TGCTs from the patients\u2019 perspective. Future research is warranted to examine the long-term benefit and risk of pexidartinib.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad282","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T19:42:29Z","timestamp":1698176549000},"page":"e535-e543","source":"Crossref","is-referenced-by-count":15,"title":["Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-0420","authenticated-orcid":false,"given":"Feng","family":"Lin","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research, Daiichi Sankyo, Inc. , Basking Ridge, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winghan","family":"Jacqueline Kwong","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Daiichi Sankyo, Inc. , Basking Ridge, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pan","sequence":"additional","affiliation":[{"name":"Epidemiology and Real-World Evidence, United BioSource LLC , Blue Bell, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5929-3798","authenticated-orcid":false,"given":"Xin","family":"Ye","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Daiichi Sankyo, Inc. , Basking Ridge, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Dai","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Daiichi Sankyo, Inc. , Basking Ridge, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tap","sequence":"additional","affiliation":[{"name":"Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"2024041017274149400_CIT0001","first-page":"34","article-title":"Diffuse-type tenosynovial giant-cell tumour: current treatment concepts and future perspectives","volume-title":"Eur J Cancer","author":"Staals","year":"2016"},{"key":"2024041017274149400_CIT0002","first-page":"100","article-title":"Tenosynovial giant-cell tumor: localized type, diffuse type","volume-title":"World Health Organization classification of tumours of soft-tissue and bone","author":"De Saint Aubain Somerhausen","year":"2013","edition":"fourth edn"},{"key":"2024041017274149400_CIT0003","first-page":"1493","article-title":"Pigmented villonodular synovitis: radiologic-pathologic correlation","volume-title":"Radiographics","author":"Murphey","year":"2008"},{"key":"2024041017274149400_CIT0004","first-page":"544","article-title":"Severity classification of Tenosynovial giant-cell tumours on MR imaging","volume-title":"Surg Oncol","author":"Mastboom","year":"2018"},{"key":"2024041017274149400_CIT0005","first-page":"688","article-title":"Higher incidence rates than previously known in tenosynovial giant-cell tumors","volume-title":"Acta Orthop","author":"Mastboom","year":"2017"},{"issue":"3","key":"2024041017274149400_CIT0006","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00005792-198005000-00004","article-title":"Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review","volume":"59","author":"Myers","year":"1980","journal-title":"Medicine (Baltim)"},{"key":"2024041017274149400_CIT0007","first-page":"1476","article-title":"Tenosynovial giant-cell tumor: incidence, prevalence, patient characteristics, and recurrence: a Registry-based cohort study in Denmark","volume-title":"J Rheumatol","author":"Ehrenstein","year":"2017"},{"key":"2024041017274149400_CIT0008","first-page":"778","article-title":"Patient-reported symptoms of tenosynovial giant-cell tumors","volume-title":"Clin Ther","author":"Gelhorn","year":"2016"},{"issue":"1","key":"2024041017274149400_CIT0009","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2196\/ijmr.9325","article-title":"The patient perspective on the impact of tenosynovial giant-cell tumors on daily living: crowdsourcing study on physical function and quality of life","volume":"7","author":"Mastboom","year":"2018","journal-title":"Interact J Med Res"},{"key":"2024041017274149400_CIT0010","first-page":"361","article-title":"Treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis","volume-title":"Curr Opin Oncol","author":"Ravi","year":"2011"},{"key":"2024041017274149400_CIT0011","first-page":"2852","article-title":"Outcomes after excision of pigmented villonodular synovitis of the knee","volume-title":"Clin Orthop Relat Res","author":"Sharma","year":"2009"},{"key":"2024041017274149400_CIT0012","first-page":"172","article-title":"What affects the recurrence and clinical outcome of pigmented villonodular synovitis","volume-title":"Clin Orthop Relat Res","author":"Chiari","year":"2006"},{"key":"2024041017274149400_CIT0013","first-page":"210","article-title":"Tenosynovial giant-cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors","volume-title":"Eur J Cancer","author":"Palmerini","year":"2015"},{"key":"2024041017274149400_CIT0014","volume-title":"Turalio [package insert]","year":"2022"},{"key":"2024041017274149400_CIT0015","first-page":"478","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant-cell tumour (ENLIVEN): a randomised phase III trial","volume-title":"Lancet","author":"Tap","year":"2019"},{"issue":"4","key":"2024041017274149400_CIT0016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17453674.2021.1922161","article-title":"Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant-cell tumor: results from the ENLIVEN randomized clinical trial","volume":"92","author":"Van De Sande","year":"2021","journal-title":"Acta Orthop"},{"key":"2024041017274149400_CIT0017","article-title":"Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant-cell tumor: results from the phase III ENLIVEN study [oral presentation]","author":"Wagner"},{"key":"2024041017274149400_CIT0018","first-page":"884","article-title":"Long-term outcomes of pexidartinib in tenosynovial giant-cell tumors","volume-title":"Cancer","author":"Gelderblom","year":"2021"},{"key":"2024041017274149400_CIT0019","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"2024041017274149400_CIT0020","first-page":"6","article-title":"The measurement of physical functioning among patients with tenosynovial giant-cell tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS)","volume-title":"J Patient Rep Outcomes","author":"Gelhorn","year":"2019"},{"key":"2024041017274149400_CIT0021","first-page":"S3","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years","volume-title":"Med Care","author":"Cella","year":"2007"},{"key":"2024041017274149400_CIT0022","first-page":"S12","article-title":"Evaluation of item candidates: the PROMIS qualitative item review","volume-title":"Med Care","author":"DeWalt","year":"2007"},{"key":"2024041017274149400_CIT0023","first-page":"17","article-title":"Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS)","volume-title":"J Clin Epidemiol","author":"Rose","year":"2008"},{"issue":"1","key":"2024041017274149400_CIT0024","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s41687-020-00217-6","article-title":"Psychometric properties of a custom Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short-form and worst stiffness numeric rating scale in tenosynovial giant-cell tumors","volume":"4","author":"Speck","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2024041017274149400_CIT0025","first-page":"105","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume-title":"J Pain","author":"Dworkin","year":"2008"},{"key":"2024041017274149400_CIT0026","first-page":"e0233046","article-title":"Long term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant-cell tumors (dTGCT)","volume-title":"PLoS One","author":"Brahmi","year":"2020"},{"key":"2024041017274149400_CIT0027","first-page":"191","article-title":"The diffuse-type tenosynovial giant-cell tumor (dt-TGCT) patient journey: a prospective multicenter study","volume-title":"Orphanet J Rare Dis","author":"Bernthal","year":"2021"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/4\/e535\/57210403\/oyad282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/4\/e535\/57210403\/oyad282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T18:15:31Z","timestamp":1712772931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/4\/e535\/7329109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10,24]]},"published-print":{"date-parts":[[2024,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad282","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2023,10,24]]}}}